FDA partially holds BioNTech's Phase 3 anti-CTLA-4, company pauses enrollment
The FDA put a partial clinical hold on a Phase 3 trial of an anti-CTLA-4 antibody from OncoC4 and its partner BioNTech, the German biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
